The use of structural distal femoral allografts for acetabular reconstruction. Average ten-year follow-up.

BACKGROUND: Acetabular fixation during revision total hip arthroplasty in patients who have a nonsupportive superior dome and proximal migration of the acetabular component (a Paprosky Type-IIIa defect) cannot be achieved reliably with use of a hemispherical porous-coated component alone. The purposes of the present study were to determine the long-term results associated with the use of a porous-coated hemispherical acetabular component, supported with a distal femoral structural allograft, for revision at the site of a Type-IIIa defect and to determine if graft resorption leads to late failure.

METHODS: Thirty-one patients who had an acetabular reconstruction with use of a distal femoral allograft for the treatment of a Type-IIIa defect between January 1985 and December 1990 were followed annually with clinical and radiographic evaluations. At the time of the latest follow-up, eight patients had died and one patient had been lost to follow-up. One of the patients who died had had a clinical failure at 4.5 years postoperatively and was included in the analysis. Therefore, twenty-three patients, who had had an average age of sixty-one years at the time of the index procedure, were evaluated at an average of 10.3 years postoperatively.

RESULTS: Five acetabular components were re-revised because of aseptic loosening at an average of 5.3 years after the index procedure. Radiographically, all but one of the remaining components were stable and showed evidence of bone ingrowth. The average Merle D'Aubigné and Postel hip score improved from 5 points preoperatively to 10 points at the time of the latest follow-up. Allograft bone resorption, although difficult to quantitate, was observed around six of the seventeen stable components and around two of the five components that failed clinically.

CONCLUSIONS: Acetabular revision with use of a porous-coated acetabular component along with a structural distal femoral allograft for the treatment of a Type-IIIa defect demonstrated a high rate of clinical and radiographic success after an average of ten years of follow-up.